A randomized controlled trial examining the efficacy of motivational counseling with observed therapy for antiretroviral therapy adherence

Kathy Goggin, Mary M Gerkovich, Karen B Williams, Julie W Banderas, Delwyn Catley, Jannette Berkley-Patton, Glenn J Wagner, James Stanford, Sally Neville, Vinutha K Kumar, David M Bamberger, Lisa A Clough, Kathy Goggin, Mary M Gerkovich, Karen B Williams, Julie W Banderas, Delwyn Catley, Jannette Berkley-Patton, Glenn J Wagner, James Stanford, Sally Neville, Vinutha K Kumar, David M Bamberger, Lisa A Clough

Abstract

This study determined whether motivational interviewing-based cognitive behavioral therapy (MI-CBT) adherence counseling combined with modified directly observed therapy (MI-CBT/mDOT) is more effective than MI-CBT counseling alone or standard care (SC) in increasing adherence over time. A three-armed randomized controlled 48-week trial with continuous electronic drug monitored adherence was conducted by randomly assigning 204 HIV-positive participants to either 10 sessions of MI-CBT counseling with mDOT for 24 weeks, 10 sessions of MI-CBT counseling alone, or SC. Poisson mixed effects regression models revealed significant interaction effects of intervention over time on non-adherence defined as percent of doses not-taken (IRR = 1.011, CI = 1.000-1.018) and percent of doses not-taken on time (IRR = 1.006, CI = 1.001-1.011) in the 30 days preceding each assessment. There were no significant differences between groups, but trends were observed for the MI-CBT/mDOT group to have greater 12 week on-time and worse 48 week adherence than the SC group. Findings of modest to null impact on adherence despite intensive interventions highlights the need for more effective interventions to maintain high adherence over time.

Figures

Fig. 1
Fig. 1
Study flowchart

References

    1. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194–200. doi: 10.1097/01.qai.0000179459.31562.16.
    1. Jones J, Taylor B, Wilkin TJ, et al. Advances in antiretroviral therapy. Top HIV Med. 2007;15:48–83.
    1. Palella FJ, Chmiel JS, Moorman AC, et al. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS. 2002;16:1617–1626. doi: 10.1097/00002030-200208160-00007.
    1. Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15:1381–1396. doi: 10.1007/s10461-011-9942-x.
    1. Sethi AK. Adherence and HIV drug resistance. HIV Clin Trials. 2004;5:112–115. doi: 10.1310/N53E-1930-NJMW-GL7C.
    1. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41:285–297. doi: 10.1097/01.qai.0000197870.99196.ea.
    1. Hill S, Kavookjian J. Motivational interviewing as a behavioral intervention to increase HAART adherence in patients who are HIV-positive: a systematic review of the literature. AIDS Care. 2012;24:583–592. doi: 10.1080/09540121.2011.630354.
    1. Simoni JM, Pearson CR, Pantalone DW, et al. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43:S23–S35. doi: 10.1097/01.qai.0000248342.05438.52.
    1. DiIorio C, Resnicow K, McDonnell M, et al. Using motivational interviewing to promote adherence to antiretroviral medications: a pilot study. J Assoc Nurses AIDS Care. 2003;14:52. doi: 10.1177/1055329002250996.
    1. Golin C, Earp J, Tien HC, et al. A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy among patients failing or initiating ART. J Acquir Immune Defic Syndr. 2006;42:42–51. doi: 10.1097/01.qai.0000219771.97303.0a.
    1. Pradier C, Bentz L, Spire B, et al. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials. 2003;4:121–131. doi: 10.1310/BRBV-3941-H1PP-NDRY.
    1. Safren SA, Otto MW, Worth JL, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-Steps and medication monitoring. Behav Res Ther. 2001;39:1151–1162. doi: 10.1016/S0005-7967(00)00091-7.
    1. Altice FL, Maru DS, Bruce RD, et al. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45:770–778. doi: 10.1086/521166.
    1. Pearson CR, Micek MA, Simoni JM, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr. 2007;46:238–244. doi: 10.1097/QAI.0b013e318153f7ba.
    1. Macalino GE, Hogan JW, Mitty JA, et al. A randomized clinical trial of community based directly observed therapy as an adherence intervention for HAART among substance abusers. AIDS. 2007;21:1473–1477. doi: 10.1097/QAD.0b013e32811ebf68.
    1. Hart JE, Jeon CY, Ivers LC, Behforouz HL, Caldas A, Drobac PC, Shin SS. Effect of directly observed therapy for highly active antiretroviral therapy on virologic immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr. 2010;54–2:167–179.
    1. Ford N, Nachega JB, Engel ME, Mills EJ. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet. 2009;374–9707:2064–2071. doi: 10.1016/S0140-6736(09)61671-8.
    1. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11–19. doi: 10.1086/505147.
    1. Beck JS. Cognitive therapy: basics and beyond. New York: The Guilford Press; 1995.
    1. Goggin K, Liston R, Mitty JA. Modified directly observed therapy for ART: a primer from the field. Public Health Rep. 2007;122:472–481.
    1. Grant KA, Tonigan JS, Miller WR. Comparison of three alcohol consumption measures: a concurrent validity study. J Stud Alcohol. 1995;56(2):168–172.
    1. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401. doi: 10.1177/014662167700100306.
    1. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004;39:609–629. doi: 10.1086/423390.
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2003) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. . Accessed 1 April 2013.
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2008) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. . Accessed 1 April 2013.
    1. Banderas J, Thomson D, Gerkovich M, et al. Value of multi-modal standard care assessment in ART adherence research. In: 5th NIMH/IAPAC International Conference on HIV Treatment Adherence, Miami, 2010.
    1. Miller W, Rollnick S. Motivational interviewing: preparing people for change. 2nd ed. New York: Guilford Press; 2002.
    1. Finocchario-Kessler S, Catley D, Thomson N, et al. Patient communication tools to enhance ART adherence counseling in low and high resource settings. Patient Educ Couns. 2012;89(1):163–170. doi: 10.1016/j.pec.2012.03.020.
    1. Harris KJ, Catley D, Good GE, et al. Motivational Interviewing for smoking cessation in college students: a group randomized controlled trial. Prev Med. 2010;51:387–393. doi: 10.1016/j.ypmed.2010.08.018.
    1. Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: poisson, overdispersed Poisson, and negative binomial models. Psychol Bull. 1995;118(3):392–404. doi: 10.1037/0033-2909.118.3.392.
    1. Simoni JM, Amico KR, Smith L, et al. Antiretroviral adherence interventions: translating research findings to the real world clinic. Current HIV/AIDS Rep. 2010;7:44–51. doi: 10.1007/s11904-009-0037-5.
    1. Sarna A, Luchters S, Geibel S, et al. Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial. J Acquir Immune Defic Syndr. 2008;48–5:611–619. doi: 10.1097/QAI.0b013e3181806bf1.
    1. Chung MH, Richardson BA, Tapia K, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med. 2011;8(3):e1000422. doi: 10.1371/journal.pmed.1000422.
    1. Parsons JT, Golub SA, Rosof E, et al. Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr. 2007;46(4):443–450. doi: 10.1097/QAI.0b013e318158a461.
    1. Safren SA, O’Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28:1–10. doi: 10.1037/a0012715.
    1. Samet JH, Horton NJ, Meli S, et al. A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems. Antivir Ther. 2005;10:83–93.
    1. Wagner GJ, Kanouse DE, Golinelli D, et al. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578) AIDS. 2006;20:1295–1302. doi: 10.1097/01.aids.0000232238.28415.d2.
    1. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25:1138–1139. doi: 10.1097/QAD.0b013e32834380c1.
    1. Haberer JE, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340–1346. doi: 10.1007/s10461-010-9799-4.
    1. Gustafson DH, Shaw BR, Isham A, Baker T, Boyle MG, Levy M. Explicating an evidence-based, theoretically informed, mobile technology-based system to improve outcomes for people in recovery for alcohol dependence. Subst Use Misuse. 2011;46(1):96–111. doi: 10.3109/10826084.2011.521413.
    1. Rasu R, Malewski D, Thomson N, et al. Cost of behavioral interventions utilizing electronic drug monitoring for antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2013;63:e1–e8. doi: 10.1097/QAI.0b013e318285d951.
    1. Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55(4):460–465. doi: 10.1097/QAI.0b013e3181f2ac87.
    1. Bangsberg DR. Modified directly observed therapy to improve HIV treatment outcomes: little impact with potent, once-daily therapy in unselected antiretroviral-naïve patients. Curr HIV/AIDS Rep. 2009;6(4):173–174. doi: 10.1007/s11904-009-0031-y.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe